New Developments in Medical Management for mCRPC
SIU Academy®. Gleave M. 09/09/13; 39144
Topic: Research
CLICK HERE TO LOGIN
REGULAR CONTENT
REGULAR CONTENT
Login now to access Regular content available to all registered users.
To have an exclusive access to the entire content available on SIU Academy, become an SIU Member here.
To have an exclusive access to the entire content available on SIU Academy, become an SIU Member here.
Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
After viewing this presentation, the participant will be able to:
Describe the current problem with castration and acquired treatment resistance in prostate cancer
Describe current treatment options for metastatic castrate-resistant prostate cancer (mCRPC), including their efficacy and limitations
List the six agents in 2013 that have shown potential to prolong survival
Provide an update on current CRPC mechanisms and novel targets, including implications for the future
Describe the current problem with castration and acquired treatment resistance in prostate cancer
Describe current treatment options for metastatic castrate-resistant prostate cancer (mCRPC), including their efficacy and limitations
List the six agents in 2013 that have shown potential to prolong survival
Provide an update on current CRPC mechanisms and novel targets, including implications for the future
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}
